Anti-Mouse CD45.2 FITC

Also known as: C57BL/6, Balb/c, Ly5.2

Clone: 104

RUO: For Research Use Only. Not for use in diagnostic procedures.

SKU# 11-0454

Cat. No. Size
11-0454-81 50 ug
11-0454-82 100 ug
11-0454-85 500 ug
Please inquire about custom configurations or bulk packaging.

To enable ordering, please select your country. Cookies will need to be enabled to continue on our website. View our Privacy Policy.

Data for Anti-Mouse CD45.2 FITC.

Staining of BALB/c splenocytes with 0.25 ug of Mouse IgG2a K Isotype Control FITC (cat. 11-4724)...View More

  • Data for Anti-Mouse CD45.2 FITC.
Description

Description: The 104 monoclonal antibody reacts with the mouse CD45 molecule, the leukocyte common antigen (LCA) in CD45.2-expressing mouse strains. The strains that express CD45.2 include the most commonly used mouse strains C57BL/6, BALB/c, C58, DBA/1, DBA/2, C3H/He, CBA, 129, A and AKR. CD45.2 is expressed by all leukocytes in these strains.

Details
Host Mouse
Isotype IgG2a, kappa
Reactivity Mouse
Conjugate FITC
Laser Blue Laser
Emit 518 nm
Excite 488 nm
Reported Applications Flow Cytometric Analysis
Documentation
TDS Link Download TDS
Additional Formats
Cat. No. Name Excite Emit Application Reg.
12-0454 Anti-Mouse CD45.2 PE 488 - 561 nm 575 nm FC RUO
14-0454 Anti-Mouse CD45.2 Purified FC, IHC, IP RUO
48-0454 Anti-Mouse CD45.2 eFluor® 450 405 nm 450 nm FC RUO
13-0454 Anti-Mouse CD45.2 Biotin FC, IHC RUO
47-0454 Anti-Mouse CD45.2 APC-eFluor® 780 633 - 647 nm 780 nm FC RUO
56-0454 Anti-Mouse CD45.2 Alexa Fluor® 700 633 - 647 nm 723 nm FC RUO
45-0454 Anti-Mouse CD45.2 PerCP-Cyanine5.5 488 nm FC RUO
17-0454 Anti-Mouse CD45.2 APC 633 - 647 nm 660 nm FC RUO
Related Products
Cat. No. Name Excite Emit Application Reg.
00-4222 Flow Cytometry Staining Buffer FC GPR
11-4724 Mouse IgG2a K Isotype Control FITC 488 nm FC, ICC, IHC RUO
References

References: Shen, F-W. (1981). Monoclonal antibodies to mouse lymphocyte differentiation alloantigens. In Monoclonal antibodies and T cell Hybridomas; Perspective and technical advances, eds. Hammerling, G.J., U. Hammerling, and J.F. Kearney: 25-31.